parnaparin

01/01/2006 - "Patients with STEMI were randomised to receive either parnaparin sodium (4250IU aXa subcutaneously every 12 hours for 7 days, initiated 12 hours after thrombolysis) or UFH (100 U/kg intravenous bolus, initiated 12 hours after thrombolytic therapy, followed by 1000 U/hour as a continuous infusion for 3 days, then 7500U subcutaneously every 12 hours for 4 days). "
01/01/2006 - "This open-label, single-centre, randomised study was conducted to compare the efficacy and safety of parnaparin sodium, a LMWH, with UFH in patients with STEMI. "
01/01/2006 - "The results of this study indicate that parnaparin sodium is more effective than UFH in reducing composite cardiac events in patients with STEMI following thrombolytic therapy. "
01/01/2008 - "Overall, the efficacy of parnaparin is at least as good as that of unfractionated heparin (UFH), but recent data indicate that parnaparin is more effective in preventing a triple composite endpoint of death, acute myocardial infarction (MI) and myocardial revascularisation in patients with unstable angina or acute ST-segment elevation myocardial infarction (STEMI). "
01/01/2004 - "To compare the efficacy and safety of unfractionated heparin with a low-molecular-weight heparin (parnaparin) in the management of anticoagulation following thrombolytic therapy for acute ST-segment elevation myocardial infarction. "

11/01/2005 - "Thus, once daily administration of parnaparin 6400 IU as a fixed dose is a safe and effective alternative to unfractionated heparin in the treatment of unstable angina."
11/01/2005 - "Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study."
11/01/2005 - "Addition of parnaparin to the standard treatment of unstable angina significantly reduced the incidence of combined triple end points of death, myocardial infarction and need for revascularization when compared to unfractionated heparin. "
11/01/2005 - "This study sought to compare the efficacy of low molecular weight heparin, parnaparin and unfractionated heparin in Indian patients presenting with unstable angina pectoris. "
01/01/2008 - "Overall, the efficacy of parnaparin is at least as good as that of unfractionated heparin (UFH), but recent data indicate that parnaparin is more effective in preventing a triple composite endpoint of death, acute myocardial infarction (MI) and myocardial revascularisation in patients with unstable angina or acute ST-segment elevation myocardial infarction (STEMI). "

07/01/2007 - "This study analyzed the efficacy of venous thromboembolism prophylaxis in knee arthroscopy in 509 patients who received Parnaparin (Alfa Wassermann, Bologna, Italy), 3200 IU to 4250 IU daily, after minor arthroscopic knee surgery. "
01/01/2008 - "Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders."
07/01/2007 - "Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin."
05/23/2015 - "Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery."
02/01/2014 - "Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study)."

01/01/2004 - "The composite triple end-point (death, recurrent myocardial infarction, emergency revascularization assessed at 2, 7, 14, 45 days) was significantly reduced in patients receiving parnaparin 42.22% vs 37.08%, P=0.03 . "
05/01/1992 - "Thus, Parnaparin may offer the advantage of a single subcutaneous injection in patients with acute myocardial infarction."
11/01/2005 - "At the end of 7 days, the primary end points (death, myocardial infarction, or need for myocardial revascularization) were reported in 33 (7.32%) patients in parnaparin group and 51 (11.43%) patients in unfractionated heparin group. "
11/01/2005 - "Addition of parnaparin to the standard treatment of unstable angina significantly reduced the incidence of combined triple end points of death, myocardial infarction and need for revascularization when compared to unfractionated heparin. "
05/01/1992 - "In this study two dosages of a new LMWH, Parnaparin, and unfractionated heparin (UF) were investigated in 50 pts with acute myocardial infarction. "

01/01/2009 - "This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies."
01/01/2006 - "The results of this study indicate that parnaparin sodium is more effective than UFH in reducing composite cardiac events in patients with STEMI following thrombolytic therapy. "